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Background: Gliomas and neuroblastomas pose a great health burden worldwide with
a poor and moderate prognosis, respectively. Many studies have tried to find effective
treatments for these primary malignant brain tumors. Of interest, the AMP-activated
protein kinase (AMPK) pathway was found to be associated with tumorigenesis and
tumor survival, leading to many studies on AMPK drugs, especially Metformin, and
their potential role as anti-cancer treatments. Cancer stem cells (CSCs) are a small
population of slowly-dividing, treatment-resistant, undifferentiated cancer cells that are
being discovered in a multitude of cancers. They are thought to be responsible for
replenishing the tumor with highly proliferative cells and increasing the risk of recurrence.
Methods: Metformin and 9-β-d-Arabinofuranosyl Adenine (Ara-a) were used to
study the role of the AMPK pathway in vitro on U251 (glioblastoma) and SH-SY5Y
(neuroblastoma) cell lines.
Results: We found that both drugs are able to decrease the survival of U251 and
SH-SY5Y cell lines in a 2D aswell as a 3D culturemodel. Metformin and Ara-a significantly
decreased the invasive ability of these cancer cell lines. Treatment with these drugs
decreased the sphere-forming units (SFU) of U251 cells, with Ara-a being more efficient,
signifying the extinction of the CSC population. However, if treatment is withdrawn before
all SFUs are extinguished, the CSCs regain some of their sphere-forming capabilities in
the case of Metformin but not Ara-a treatment.
Conclusion: Metformin and Ara-a have proved to be effective in the treatment of
glioblastomas and neuroblastomas, in vitro, by targeting their cancer stem/progenitor
cell population, which prevents recurrence.
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INTRODUCTION
Primary malignant tumors of the brain and central nervous
system (CNS) are estimated to have a yearly incidence rate of
about 7.25 per 100,000 in the United States (Ostrom et al., 2014).
Gliomas are among the most common and detrimental brain
cancers with amean survival time of about 1.5 years (Chang et al.,
2006). On the other hand, neuroblastoma is the most common
extra-cranial solid tumor in the pediatric age group, with a
survival rate ranging between 30 and 90% (Schmidt et al., 2000;
Gatta et al., 2002; Maris, 2010). To this date, the treatment for
gliomas and neuroblastoma consists of total surgical resection,
radiotherapy and chemotherapy (Sathornsumetee et al., 2007;
Irwin and Park, 2015). Many studies have utilized different
approaches to target various elements contributing to the
development of these malignancies.
One element that is gaining increasing interest in cancer
treatment is the cancer stem cell (CSC) population found
within the primary tumor bulk. CSCs are believed to be the
reason behind the initiation, growth, metastasis, and recurrence
of tumors as they exhibit self-renewal, differentiation, and
tumorigenic properties (Visvader, 2011; Magee et al., 2012). The
hallmark of CSC viability is their ability to withstand the potency
of conventional therapy, specifically via multi-drug resistance
rendering the need for a more targeted approach for therapy
(Abdullah and Chow, 2013). The existence of CSCs has been
documented in many types of cancers, including gliomas and
neuroblastomas (Walton et al., 2004; Chen et al., 2012).
Metformin, usually used as a first line treatment for Type
II Diabetes Mellitus, has shown significant promises in treating
different types of cancer (Najbauer et al., 2014; Deng et al.,
2015; Fujihara et al., 2015). The interest in using Metformin
in cancer research arose when several epidemiological studies
revealed a lower incidence of cancer in diabetic patients on
metformin therapy as compared to patients who are not (Hwang
et al., 2015). Metformin, an adenosine monophosphate-activated
protein kinase (AMPK) activator, was effective in suppressing
and killing glioma and neuroblastoma cells (Isakovic et al.,
2007; Shackelford and Shaw, 2009; Kumar et al., 2014; Liu
et al., 2014). Furthermore, Metformin proved that it could
target the CSC population in glioblastoma tumors (Wurth et al.,
2013), rendering it a good adjuvant chemotherapeutic agent. On
the other hand, the AMPK inhibitor, 9-β-d-Arabinofuranosyl
Adenine (Ara-a), has been mostly used as an inhibitor of
Metformin’s effect (Takatani et al., 2011), and studies focused
on its derivatives in having effective anti-cancerous properties
in hematologic malignancies (White et al., 1982; Bogdahn et al.,
1987a,b; Lozano-Santos et al., 2015; Sharma et al., 2015c; Valdez
et al., 2015).
In this study, we investigated the potency of Metformin and
Ara-a in suppressing the proliferation, viability, and invasive
potential of the glioblastoma and neuroblastoma cell lines U251
and SH-SY5Y, respectively. We further focused on the effect of
these drugs on the CSC population among these cell lines within a
3Dmodel, by using the sphere formation assay within Matrigel™
(Abou-Kheir et al., 2010, 2011; El-Merahbi et al., 2014). We
studied the effect of these drugs over five consecutive generations
of sphere-formation to determine the potency of abolishing the
CSC population.
MATERIALS AND METHODS
Cell Culture and Treatments
U251 and SH-SY5Y cells (ATCC, USA) were cultured and
maintained in Dubelcco’s Modified Eagle Media (DMEM)
Ham’s F-12 (Sigma-Aldrich) supplemented with 10% heat
inactivated fetal bovine serum (FBS) (Sigma-Aldrich) and 1%
Penicillin/Streptomycin (Sigma-Aldrich). Cells were incubated at
37◦C in a humidified incubator containing 5% CO2. The drugs
Metformin and Ara-a were purchased from Sigma-Aldrich and
were both reconstituted in dimethyl sulfoxide (DMSO).
MTT/Cell Viability Assay
The anti-proliferative effects of Metformin and Ara-a were
measured in vitro by using MTT [(3-(4, 5-dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide)] assay according to the
manufacturer’s instructions (Roche). Briefly, cells were seeded
(1× 104 cells/well) in 100µl complete medium in three different
96-well plates—one plate per time point (24, 48, 72 h)—and
incubated overnight at 37◦C, 5% CO2 before being exposed to
the different treatments. At each time point, media was removed
and replaced with fresh media along with 10µl/well of the MTT
yellow dye and incubated for 4 h, after which 100µl/well of the
solubilizing agent was added and incubated overnight at 37◦C,
5% CO2. Absorbance intensity was measured by the microplate
ELISA reader (Multiscan EX) at 595 nm. The percentage of cell
viability was presented as an optical density (OD) ratio of the
treated to the untreated cells.
Wound Healing Assay
SH-SY5Y and U251 cells were cultured in six-well plates (5× 105
cells/well) and incubated at 37◦C, 5% CO2 until they reached
90–100% confluence. Cells were then treated with 10mg/ml
of Mitomycin C (Sigma) for 2 h in order to block cellular
proliferation. A sterile 200µl tip was used to create scratch
wounds of the same width on each monolayer. The plates
were then washed twice with phosphate-buffered saline (PBS)
to remove the detached cells, and the remaining cells were
cultured in complete media with or without treatment. Photos
were taken at 0, 24, and 48 h, and the distance traveled by the
cells enumerated the closure of the wounds.
Trans-well Invasion Assay
SH-SY5Y and U251 cells were seeded in the top chamber of
Matrigel™-coated inserts (pore size: 8µm; Falcon) placed in 24-
well plates (2×105cells/well), while amedium supplemented with
10% FBS was used as a chemo-attractant in the lower chamber.
The wells were coated with 100ml of Matrigel™ (BD Bioscience)
at a dilution of 1:10 in cold PBS and air-dried overnight in a
biosafety cabinet. The cells were allowed to invade through the
Matrigel™ for 24 h at 37◦C in a 5% CO2 incubator. Cells that
did not invade were scraped off with a cotton-tip applicator while
the invading cells were fixed and stained with Hematoxylin and
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Eosin. The number of invading cells was counted under a light
microscope (x10 objective) from six consecutive fields for each
well.
3D Culture and Sphere-formation Assay
Single SH-SY5Y and U251 cell suspension were suspended
in Matrigel™/serum free DMEM (1:1) at a concentration of
104cells/well in a total volume of 50µl. The solution was then
plated gently around the rim of individual wells of a 24-well plate
and allowed to solidify for 1 h at 37◦C in a humidified incubator
containing 5% CO2. 0.5ml of DMEM with 2% FBS (for U251) or
5% FBS (for SH-SY5Y) was added gently to the center of each well
and the media (containing the treatment) was changed every 2–3
days. Spheres were counted and/or harvested at day 9 (for U251)
or day 14 (for SH-SY5Y) after plating. For sphere propagation,
the medium was aspirated and the Matrigel™ was digested
with 0.5ml Dispase solution (Invitrogen, Carlsbad, CA, 1mg/ml,
dissolved in serum-free DMEM Ham’s F-12) for 60min at 37◦C.
Spheres were collected, incubated in 1ml warm Trypsin- EDTA
at 37◦C for 5min, and then passed through a 27-gauge syringe
five times. Cells were counted by a hemocytometer and re-seeded
at 104cells/well. The sphere-forming unit (SFU), expressed as %,
was calculated by dividing the number of spheres counted by the
number of input cells (104 cells) and thenmultiplied by 100. Zeiss
Axiovert microscope was used for the acquisition of bright field
images.
Zymography
SH-SY5Y and U251 cells were cultured in petri dishes and
incubated at 37◦C, 5% CO2. The cells were then treated for
24 h, after which the media was collected in falcon conical tubes
and stored at −80◦C. Protein quantification was done using
the Detergent Compatible (DC) Protein Assay (Bio-Rad) as
per manufacturer’s recommendations, employing bovine serum
albumin as a standard. Finally, equal amount of proteins were
re-suspended in sample buffer in the absence of reducing
agents and loaded onto 7% polyacrylamide gels impregnated
with gelatin (3mg/ml). Protein-containing culture supernatant
was then loaded in sodium dodecyl sulfate-polyacrylamide
gel (100µg/well), subjected to electrophoresis and run at low
temperature (apparatus placed on ice). Gels were then washed
twice at room temperature for 30min in a 2.5% Triton X-100
solution in IX running buffer. After that, gels were incubated for
24 h in substrate buffer (50mM Tris-HCl, 5mM CaCl2, 0.02%
NaN3, pH 8.0) at 37
◦C, and stained for 2 h, at room temperature,
in 0.05% Coomassie blue R-250, in 50% methanol, and 10%
acetic acid. Gel destaining with water took place overnight
and gelatinases were visualized as clear white bands reflecting
digestion of the gel by matrix metalloproteinase (MMP). MMP-2
intensity was calculated by measuring the band size via Image J
software.
Data Analysis
Statistical analysis was performed using Statistical Package for
Social Sciences program (SPSS) version 20. The significance of
the data was analyzed using a Student’s t-test, and p-values of
p < 0.05 (∗) and p < 0.01 (∗∗) were considered significant and
highly significant, respectively.
RESULTS
Metformin and Ara-a Inhibit U251 and
SH-SY5Y Cell Proliferation in a Dose- and
Time-dependent Manner
We first studied the in vitro effect of Metformin and Ara-a on the
cell proliferation of both cell lines, via MTT assays (Figure 1A).
Knowing that the SH-SY5Y cell line has both adherent and
floating cells, the media, including floating cells, was removed
and thus the MTT results are only reflective of the adherent cells.
We found that Metformin similarly decreased the proliferative
activity of both U251 and SH-SY5Y cell lines, reaching an
inhibitory effect of around 50% at 72 h at 5mM for U251 and
at 10mM for SH-SY5Y. On the other hand, Ara-a revealed
a more potent effect and at a lower concentration, compared
to Metformin. There was a 50% inhibitory effect on SH-SY5Y
proliferation at 72 h at 4mM, while the same inhibitory effect
was achieved on U251 cells after 24 and 48 h of 2mM and 1mM
of Ara-a treatment, respectively. Furthermore, we noticed that
in addition to inhibiting cell proliferation, Metformin and Ara-
a induced cell death in both cell lines, as measured by trypan
blue exclusion method (data not shown). The morphological and
confluency changes following drug treatment in both cell lines
after 48 h are shown in Figure 1B.
Metformin and Ara-a Inhibit the Migratory
and Invasive Ability of Cancer Cell Lines
We then investigated the effect of our drugs on cell migration and
invasion, which are two major pillars of cancer metastasis and,
in turn, prognosis. A wound-healing assay was performed on
U251 in the presence of Mitomycin C, a proliferation inhibitor.
Mitomycin C was not used in the migration assay of SH-SY5Y
since it led to their death. Both Metformin and Ara-a were
able to significantly suppress the migration of U251 cells, while
the untreated cells were able to completely close the wound
at 48 h (Figures 2A,C). Even though untreated SH-SY5Y cells
were not able to completely close the wound at 48 h, both
drugs similarly significantly inhibited the migration of treated
cells (Figures 2B,D). This shows that Metformin and Ara-a can
suppress the metastatic ability of both cancer cell lines. These
results were also compatible with the trans-well invasion assay on
U251 cells, whereby Metformin significantly decreased invasion
by around 2.5 folds while Ara-a reduced invasion even more, by
around seven folds (Figure 3B). The assay was not performed
on SH-SY5Y cells since they failed to show an ability to invade
when using FBS as a chemo-attractant. This shows that both
Metformin and Ara-a are capable of reducing the invasive ability
of glioblastoma.
Metformin and Ara-a Inhibit the Secretion
of MMP-2
Matrix metalloproteinases are known to aid cancer cells in
digesting their surrounding matrix and increasing their ability
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FIGURE 1 | The effect of Metformin and Ara-a on the proliferation, morphological, and confluence changes of U251 and SH-SY5Y cell lines. (A) After
incubation of the two cell lines (U251 and SH-SY5Y) for 24, 48, and 72 h with or without treatment with Metformin or Ara-a at different concentrations, cell proliferation
was determined using MTT assay. Results are expressed as a percentage of the treated group compared to its control. Data represent an average of three
independent experiments. The data are reported as mean ± SEM (**P < 0.01). (B) Representative images of U251 and SH-SY5Y cells were taken after 48 h in culture
with or without Metformin and Ara-a treatment. Cells were visualized by Axiovert inverted microscope from Zeiss at 4x magnification.
to invade through the basement membrane (Gialeli et al., 2011).
This is clinically significant in the sense that MMP production
by tumor cells could aid their metastasis to other sites of the
body and thus make cancer treatment even more cumbersome.
We sought to assess the effect of our drugs on the production
of MMP-2 and MMP-9. Zymography electrophoretic technique
was performed to detect changes in the production of both
MMPs, following treatment. As a result, we found that only
Metformin significantly decreases the production of MMP-2 in
both cells lines, while Ara-a affects U251 cells only (Figure 3A).
Furthermore, the effect of both drugs on MMP-2 production
was more potent on U251 compared to SH-SY5Y cell lines.
MMP-9 was secreted in negligible amounts by neuroblastoma
and glioblastoma cell lines and both drugs had no effect on its
production (data not shown).
Sphere Forming Capability of U251 and
SH-SY5Y
In order to better visualize their sphere-forming capabilities,
single cell suspensions of U251 and SH-SY5Y were cultured in
Matrigel™ for 9 and 14 days, respectively. The spheres were
then visualized under an inverted light microscope and bright-
field images were acquired (Figure 4A). U251 cell line produced
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FIGURE 2 | Metformin and Ara-a reduce the migratory and invasive potentials of human neuronal and glial cancer cell lines. A scratch was made in
a six-well plate of confluent U251 cells with Mitomycin C (A) and SH-SY5Y cells without Mitomycin C (B), using a 200µl tip, and images were taken at T = 0,
24, and 48 h with or without treatment, and quantification of the distance of the wound closure was assessed over time (C,D). Results are expressed as a
percentage of each group compared to its condition at T = 0 h. Data represent an average of three independent experiments. The data are reported as mean ±
SEM (**P < 0.01).
more and relatively larger spheres compared to those of SH-SY5Y
(Figures 4A,B).
Metformin and Ara-a Target an Enriched
Population of U251 and SH-SY5Y Cancer
Stem/Progenitor Cells
Our main focus in this study is to see the potential inhibitory
effects of Metformin and Ara-a on tumor survival by targeting
its CSC population in vitro, which is translated by the ability
to form and propagate spheres. Neurospheres were generated
from 10,000 single cells of U251 and SH-SY5Y, embedded in
Matrigel™. After culturing U251 and SH-SY5Y cells for 9 and
14 days, respectively, we got an SFU of around 3.4 and 1%
for each of U251 and SH-SY5Y, respectively (Figure 4C). The
number and size of cultured neurospheres decreased in a dose-
dependent manner for both drugs (Figure 4C), whereby the
number of spheres were significantly decreased in both cell lines
at 1 and 5mM of Metformin and at 10, 50, and 100µM of Ara-
a. Treatment with 1mM of Metformin significantly decreased
neurosphere formation by around 33% and 50% for U251 and
SH-SY5Y cell lines, respectively. On the other hand, 10µM of
Ara-a significantly decreased sphere formation in both cell lines
by around 50%. We noticed that the effect of Metformin and
Ara-a was more pronounced on the 3D culture compared to 2D,
whereby a lower concentration of each drug, specifically Ara-a,
led to a stronger anti-survival effect on the cancer cells.
Being the hallmark of stem/progenitor cells, we investigated
the effect of Metformin and Ara-a on the neurosphere self-
renewal activity, by assessing sphere formation capability over
five generations. Since SH-SY5Y cell lines did not survive
propagation, this assessment was only done on the U251 cell line,
whereby U251 spheres of the first generation (G1) were collected
and propagated by dissociating them into single cells and
reseeding the same number of cells used initially (104cell/well).
The experimental design of this assay is illustrated in Figure 5.
Treatment with 1mM of Metformin led to around 33% decrease
in sphere formation in G1, whereas treatment with 10µM of
Ara-a led to around 50% decrease in sphere formation in G1
(Figure 5A). After enriching for cancer stem/progenitor cells
by propagating untreated cells, treatment of U251 neurospheres
at G5 with either Metformin or Ara-a yielded approximately
the same decrease in SFU as that witnessed when treating G1
spheres (Figure 5A). Upon successive propagation and treatment
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FIGURE 3 | The effect on matrix metalloproteinase-2 (MMP-2) production and invasion potential. (A) After seeding U251 and SH-SY5Y cell lines and
treating them with 10mM of Metformin or 4mM of Ara-a, the culture supernatant was collected and zymography was performed to detect changes in MMP-2
production following treatment, which are reflected in changes in gel digestion band size. The band size was measured via Image J software. Results are expressed
as a percentage of the treated group compared to its control. Data represent an average of three independent experiments. The data are reported as mean ± SEM
(*P < 0.05). (B) U251 cells were seeded onto the MatrigelTM-coated membrane in the top chamber of the trans-well and were either treated or not treated with 5mM
of Metformin or 2mM of Ara-a in the presence of FBS in the lower chamber. Cells that invaded to the lower chamber after 24 h were fixed with methanol, stained with
Hematoxylin and Eosin, counted and represented as a number of invaded cells. Data represent an average of three independent experiments. The data are reported
as mean ± SEM (**P < 0.01).
of cells, SFU progressively decreased to reach 0% at G3 after
continuous Metformin treatment (Figure 5B). Ara-a was even
more potent in reducing the SFU of U251 cells whereby most
propagations ended in an SFU of 0% by the fourth generation,
while most of the Metformin-treated spheres remained viable up
till the fifth generation (Figure 5C). Interestingly, it was noted
that upon withdrawal of Metformin treatment in the subsequent
generation, the neurospheres were able to regain some of their
sphere-forming ability, yet this was not the case with Ara-a,
whereby after one Ara-a treatment, the subsequent untreated
generations produced a lower SFU.
DISCUSSION
Cancer therapy is always evolving to become more potent
and efficient in eradicating tumors with the least number of
side effects on the patient. Biochemical and molecular studies
of oncogenesis have investigated the contribution of various
parameters involved in the pathogenesis of cancer, including
the AMPK pathway (Godlewski et al., 2010; Laderoute et al.,
2014; Tan et al., 2014; Kim et al., 2015; Sujobert et al., 2015).
In addition to its anti-cancerous effects, activating the AMPK
pathway via Metformin was shown to be protective against
neuro-degeneration by inhibiting the formation of advanced
glycosylation end products, which reduce the expression of
neuro-protective genes (Bcl-2, CREB and PPARγ) (Chung et al.,
2015). Thus, by interfering in the LKB1/AMPK/mTOR/S6K1
pathway, Metformin seems to be a promising drug in the field
of neuro-oncology whereby it can destroy cancerous brain cells
and their CSCs (Carmignani et al., 2014), revitalize healthy
neurons, and even prevent chemotherapy-induced neuropathy
(Mao-Ying et al., 2014). With the AMPK pathway proving to be
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FIGURE 4 | Effect of Metformin and Ara-a on the sphere-forming ability of human neuronal and glial cancer cell lines. (A) Representative bright-field
images of U251 and SH-SY5Y neurospheres with or without Metformin and Ara-a treatment. Images were visualized by Axiovert inverted microscope at 10x
magnification and analyzed by Carl Zeiss Zen 2012 image software. (B) Quantification of the average size of U251 and SH-SY5Y neurospheres with or without
treatment conditions. Data represent an average area (µm2) of 20 measured U251 spheres and 10 measured SH-SY5Y spheres. The data are reported as mean ±
SEM (**P < 0.01). (C) Increasing the concentration of treatment of both Metformin and Ara-a on U251 and SH-SY5Y spheres, cultured in MatrigelTM, led to a similar
decrease in the number of Sphere Forming Units (SFU) in both cell lines. The generated spheres are referred to as G1 (Generation 1) spheres. Results are expressed
as SFU which is calculated according to the following formula: SFU = (number of spheres counted x number of input cells) × 100. Data represent an average of three
independent experiments. The data are reported as mean ± SEM (*P < 0.05; **P < 0.01).
a good therapeutic target, and our belief that eradicating CSCs
is the hallmark for a long-term cure of cancer, we conducted
this study to investigate the role of an AMPK activator and
inhibitor on the survival of cancer cell lines and their CSC
population.
This study showed that both drugs, Metformin and Ara-a
significantly affect the proliferation and survival of cancer cells of
brain origin. The fact that both drugs decrease viability yet work
antagonistically on the AMPK pathway, we hypothesize that each
drug may be affecting alternative pathways. One explanation
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FIGURE 5 | Metformin and Ara-a inhibit the self-renewal ability of the glial cancer stem/progenitor cells. (A) SFU obtained from serially passaged U251
neurospheres over five generations is shown under untreated conditions (always control) and with 1mM Metformin and 10µM Ara-a-treated condition (treated once at
G1 and at G5). (B,C) Glial CSC were enriched from U251 cell line and treated with either Metformin (1mM) (B) or Ara-a (10µM) (C). After each propagation, cells that
were initially treated with Metformin, Ara-a or media (control) were seeded into separate wells. Spheres were propagated for five generations. SFU is counted and an
average of two independent experiments is represented. The data are reported as mean ± SD.
is that AMPK activation leads to the inhibition of the mTOR
pathway, in addition to the fact that Metformin itself inhibits
the Akt (Wurth et al., 2013) and mTOR pathway (Yu et al.,
2015), which is downstream of both Akt and AMPK. Both the
mTOR and Akt pathways have been implicated in various types
of cancers (Vivanco and Sawyers, 2002; Hsieh et al., 2015; Sharma
et al., 2015b; Wang et al., 2015). On the other hand, given that
the AMPK pathway directs cellular signaling into a catabolic
state to produce ATP in the case of cellular energy deficiency
(Viollet et al., 2010; Egan et al., 2011; Suzuki et al., 2013), Ara-
a-induced inhibition of AMPK may be depriving the cancer cells
from producing the energy they need to survive. Yet, Ara-a is a
nucleoside analog and can interfere with DNA synthesis and may
thus exert anti-cancerous effects via that mechanism which may
explain the higher potency of Ara-a compared to Metformin.
Another mechanism in which these drugs were affecting
these cells and inducing their death was mediated via the
increase of intracellular calcium (data not shown), which
prompts further investigations in future studies to elucidate
the exact mechanisms mediating the anti-cancerous effects.
Furthermore, both Metformin and Ara-a had an inhibitory effect
on the invasive ability of both glial and neuronal cancer cells,
possibly through decreasing MMP-2 production that is known
to have a role in cancer progression by aiding extracellular
matrix degradation. This could provide cancer patients with a
great benefit in terms of increasing their survival and disease
prognosis. With gliomas being extremely fatal due to their
enormous proliferative and invasive capacity, these drugs could
at least significantly hinder disease progression, allowing an
easier brain excision with the least complications possible.
Most importantly, we studied the effect of the AMPK activator
and inhibitor on the stem cell population within the cell lines.
The existence of a CSC population within different types of
tumors are continuously being uncovered and this population of
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cells have been correlated with a poorer prognosis, irrespective
of the type of cancer. These included cancers of the brain,
blood, ovaries, colon, breast and prostate (Asfaha et al., 2015;
Duru et al., 2015; Huang et al., 2015; Kato et al., 2015; Li
et al., 2015; Yin et al., 2015). Many studies are currently being
conducted to phenotype these cells and understand their genetic
makeup and the regulatory pathways involved in guiding their
cell cycle as undifferentiated cells having progenitor stem-like
properties (Fares et al., 2015; Mathur et al., 2015; Moreira et al.,
2015; Sharma et al., 2015a). Unfortunately, most current anti-
cancer treatments target the highly proliferative cancer cells,
constituting the bulk of the tumor, while missing the slowly
dividing treatment-resistant stem cells that is believed to lead to
cancer recurrence after an apparent remission (Yu et al., 2012).
After finishing all the cycles of cancer treatment and entering a
phase of remission, these few CSCs could replenish the eradicated
progenitor cells, which in turn re-establish the tumor. Thus, it is
crucial to use a drug that targets this small CSC population in
order to ensure the prevention of a recurrence. That is why we
studied the ability of Metformin and Ara-a in depleting glioma
CSCs, via assessing their effect on sphere-formation.
We found that both drugs significantly decrease the number
and size of SFUs, and this effect is additive with higher
concentrations and as the spheres are passaged into subsequent
generations, with Ara-a being more potent and efficient than
Metformin. However, we noticed that some of the sphere-
forming capabilities are regained if Metformin treatment is
withdrawn after passaging the spheres, but can be inhibited
again with another cycle of treatment. This shows that a serial
treatment withMetformin is needed to completely and efficiently
destroy the CSC population and prevent tumor recurrence. On
the other hand, the effect of a single Ara-a treatment on G1
could still be observed until the fifth generation of U251 spheres.
It seems that Ara-a has a unique mechanism of action, unlike
Metformin, that progressively decreases cell viability and sphere-
forming capacity of CSCs even after the removal of the trigger
(Ara-a), and this mechanism is further enhanced if the spheres
are treated again. This lingering effect could be due to the fact that
once the cells are exposed to Ara-a, it constantly disrupts their
DNA synthesis by becoming incorporated into the CSC DNA as
Ara-ATP. Noteworthy, Metformin turned out to be selectively
anti-cancerous against CSCs compared to their differentiated
cancer counterparts, for both U251 and SH-SY5Y. On the other
hand, in addition to being potently anti-cancerous against the
CSCs of U251 and SH-SY5Y, Ara-a also effectively eradicated the
highly proliferative U251 cells but not the SH-SY5Y. This goes
to show that with Metformin and Ara-a being effective against
CSCs, an adjunct drug/therapy could be utilized to efficiently
target the highly proliferative cells comprising the tumor bulk of
brain cancer.
In conclusion, our study reveals that targeting the AMPK
pathway, through an inducer or inhibitor, presents an effective
anti-cancerous treatment whereby they target the main pillars
of its fatality, namely its metastatic and regenerative properties.
Optimizing the treatment of Metformin and/or Ara-a could be
sufficient in eradicating brain tumors by killing the proliferating
cells, inhibiting recurrence by depleting the CSC population over
several generations via successive treatments, and preventing
their metastasis to other organs, which ultimately increase the
severity of multi-organ cancer complications. More importantly,
our study showed that using an AMPK inhibitor was not only
effective but even more potent than an inducer, in the treatment
of brain cancer and its CSCs. This requires further investigations
on AMPK inhibition to assess the differentially regulated genes
that are leading to the potent effect of Ara-a on cancer cells. It
is also worth assessing for the presence of the same cytotoxic
effect on healthy neurons and glial cells. Future studies need to be
done to further assess the effectiveness of these drugs, specifically
Ara-a, on the CSCs in animal and human tumors of the brain
and other organs, whereby their inclusion as adjuncts in current
anti-cancer treatments could provide better therapeutic results.
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